{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:37:51Z","timestamp":1786711071374,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polymyxin remain essential last-line agents for the treatment of multidrug-resistant gram-negative infections in critically ill patients. However, dosing polymyxin B and colistin in patients with renal impairment is clinically challenging due to complex pharmacokinetics, fluctuating renal function, toxicity concerns and limited implementation of therapeutic drug monitoring. While pharmacokinetic and guideline-based recommendations exist, little is known about how clinicians navigate these complexities in real-world practice. We conducted an inductive qualitative study using semi-structured interviews with physicians involved in the management of critically ill patients with severe gram-negative infections. Participants were purposively sampled from critical care, nephrology, infectious diseases and general medicine. Interviews explored experiences and decision-making related to polymyxin selection, dosing adjustments, renal dysfunction, renal replacement therapy, safety monitoring and institutional influences. Transcripts were analysed using a constructivist grounded theory approach, following iterative coding, constant comparison and theme development. Coding and analysis were performed using ATLAS.ti software. Reporting adhered to the COREQ checklist. Seventeen physicians were interviewed. Analysis yielded six interrelated themes: 1. Clinical determinants of polymyxin selection, 2. Individualized and adaptive dosing practices, 3. Renal dysfunction and renal replacement therapy-related uncertainty, 4. Safety-driven decision-making, 5. Monitoring, diagnostic, and evidence limitations, and vi. Institutional and system-level influences. Clinicians described polymyxin dosing as a dynamic experience-driven process requiring continuous reassessment and risk\u2013benefit negotiation. Renal function variability, lack of therapeutic drug monitoring, and absence of standardized institutional protocols contributed to cautious and heterogenous dosing practices, particularly in patients receiving dialysis. Polymyxin dosing in critically ill patients with renal impairment is shaped by complex clinical judgement, safety concerns and systemic constraints rather than rigid adherence to dosing algorithms. These findings highlight a gap between pharmacokinetic evidence and bedside practice and underscore the need for pragmatic, context-appropriate dosing guidance, multidisciplinary stewardship support and decision-support tools to optimize polymyxin use in high-risk populations.<\/jats:p>","DOI":"10.1038\/s41598-026-55210-8","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:05:50Z","timestamp":1780542350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinician decision-making for polymyxin dosing in critically ill patients with renal impairment: a qualitative study"],"prefix":"10.1038","volume":"16","author":[{"given":"Asha K.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayanarayana","family":"Kunhikatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Prabhu Attur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-969X","authenticated-orcid":false,"given":"Girish","family":"Thunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"55210_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11131946","volume":"11","author":"MA Salam","year":"2023","unstructured":"Salam, M. A. et al. Antimicrobial resistance: A growing serious threat for global public health. Healthcare 11, 1946 (2023).","journal-title":"Healthcare"},{"key":"55210_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13121136","volume":"13","author":"M Lagadinou","year":"2024","unstructured":"Lagadinou, M. et al. Antibiotic resistance trends in carbapenem-resistant Gram-negative pathogens and eight-year surveillance of XDR bloodstream infections in a Western Greece tertiary hospital. Pathogens 13, 1136 (2024).","journal-title":"Pathogens"},{"key":"55210_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12081317","volume":"12","author":"RCL Garcia","year":"2023","unstructured":"Garcia, R. C. L., Rodrigues, R. D., Garcia, E. C. L. & Rigatto, M. H. Comparison between colistin and polymyxin B in the treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex. Antibiotics 12, 1317 (2023).","journal-title":"Antibiotics"},{"key":"55210_CR4","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s40121-025-01213-3","volume":"14","author":"Q Peng","year":"2025","unstructured":"Peng, Q. et al. Optimizing polymyxin B therapy in critical care: Pharmacokinetic insights and clinical outcomes in a retrospective cohort study. Infect. Dis. Ther. 14, 2565\u20132582 (2025).","journal-title":"Infect. Dis. Ther."},{"key":"55210_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji, B. T. et al. International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39, 10\u201339 (2019).","journal-title":"Pharmacotherapy"},{"key":"55210_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri, A. M. et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin. Infect. Dis. 57, 524\u2013531 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"55210_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01337-16","volume":"61","author":"V Thamlikitkul","year":"2017","unstructured":"Thamlikitkul, V. et al. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency. Antimicrob. Agents. Chemother. 61, e01337-16 (2017).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"55210_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17460913.2025.2600243","volume":"20","author":"TJ Nolan","year":"2025","unstructured":"Nolan, T. J. & Martin-Loeches, I. Antimicrobial stewardship in critical care. Future. Microbiol. 20, 1225\u20131235 (2025).","journal-title":"Future. Microbiol."},{"key":"55210_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09759-2","volume":"24","author":"P Aysert-Yildiz","year":"2024","unstructured":"Aysert-Yildiz, P. et al. Polymyxin B vs. colistin: The comparison of neurotoxic and nephrotoxic effects of the two polymyxins. BMC. Infect. Dis. 24, 862 (2024).","journal-title":"BMC. Infect. Dis."},{"key":"55210_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1424765","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang, S., Wang, H., Zhao, D., Zhang, S. & Hu, C. Polymyxins: Recent advances and challenges. Front. Pharmacol. 15, 1424765 (2024).","journal-title":"Front. Pharmacol."},{"key":"55210_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1586\/14787210.2014.902307","volume":"12","author":"AP Zavascki","year":"2014","unstructured":"Zavascki, A. P. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: From pharmacokinetics to bedside. Expert. Rev. Anti. Infect. Ther. 12, 531\u2013533 (2014).","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"55210_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.975066","author":"Z Yu","year":"2022","unstructured":"Yu, Z. et al. Pharmacokinetics\/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.975066 (2022).","journal-title":"Front. Pharmacol."},{"key":"55210_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.cmi.2017.03.013","volume":"23","author":"E Charani","year":"2017","unstructured":"Charani, E. et al. Understanding antibiotic decision making in surgery\u2014A qualitative analysis. Clin. Microbiol. Infect. 23, 752\u2013760 (2017).","journal-title":"Clin. Microbiol. Infect."},{"key":"55210_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/1440783315594486","volume":"52","author":"A Broom","year":"2016","unstructured":"Broom, A., Broom, J., Kirby, E. & Adams, J. The social dynamics of antibiotic use in an Australian hospital. J. Sociol. 52, 824\u2013839 (2016).","journal-title":"J. Sociol."},{"key":"55210_CR15","volume-title":"Constructing Grounded Theory","author":"K Charmaz","year":"2014","unstructured":"Charmaz, K. Constructing Grounded Theory (SAGE, 2014)."},{"key":"55210_CR16","unstructured":"ATLAS.ti | The #1 Software for Qualitative Data Analysis. ATLAS.ti https:\/\/atlasti.com."},{"key":"55210_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40262-025-01488-2","volume":"64","author":"PJ Zamri","year":"2025","unstructured":"Zamri, P. J., Lim, S. M. S., Sime, F. B., Roberts, J. A. & Abdul-Aziz, M. H. A systematic review of pharmacokinetic studies of colistin and polymyxin B in adult populations. Clin. Pharmacokinet. 64, 655\u2013689 (2025).","journal-title":"Clin. Pharmacokinet."},{"key":"55210_CR18","doi-asserted-by":"publisher","unstructured":"Trautner, B. W. et al. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI. Clin Infect Dis 460 (2025). https:\/\/doi.org\/10.1093\/cid\/ciaf460.","DOI":"10.1093\/cid\/ciaf460"},{"key":"55210_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/cid\/ciu213","volume":"59","author":"RL Nation","year":"2014","unstructured":"Nation, R. L., Velkov, T. & Li, J. Colistin and polymyxin B: Peas in a pod, or chalk and cheese?. Clin. Infect. Dis. 59, 88\u201394 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"55210_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran, T. B. et al. Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: Are we there yet?. Int. J. Antimicrob. Agents. 48, 592\u2013597 (2016).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"55210_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/cpt.3729","volume":"118","author":"PO Hanafin","year":"2025","unstructured":"Hanafin, P. O. et al. Population pharmacokinetic\/toxicodynamic model for polymyxin B in critically ill patients to identify the risk of nephrotoxicity. Clin. Pharmacol. Ther. 118, 841\u2013852 (2025).","journal-title":"Clin. Pharmacol. Ther."},{"key":"55210_CR22","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.cmi.2023.05.018","volume":"29","author":"PO Hanafin","year":"2023","unstructured":"Hanafin, P. O. et al. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clin. Microbiol. Infect. 29, 1174\u20131181 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"55210_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14121286","volume":"14","author":"G Kaspute","year":"2025","unstructured":"Kaspute, G. & Ivaskiene, T. Pharmacist-led diagnostics: A new frontier in antimicrobial stewardship. Antibiotics 14, 1286 (2025).","journal-title":"Antibiotics"},{"key":"55210_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11851-0","volume":"25","author":"R Rajendran","year":"2025","unstructured":"Rajendran, R. et al. Antimicrobial stewardship programs in primary and secondary care settings in India: Current challenges, facilitators, perceptions, and impact\u2014A scoping review. BMC. Infect. Dis. 25, 1539 (2025).","journal-title":"BMC. Infect. Dis."},{"key":"55210_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727170","volume":"12","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients. Front. Pharmacol. 12, 727170 (2021).","journal-title":"Front. Pharmacol."},{"key":"55210_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70110","volume":"17","author":"Y Fang","year":"2024","unstructured":"Fang, Y. et al. Pharmacokinetic study of polymyxin B in healthy subjects and subjects with renal insufficiency. Clin. Transl. Sci. 17, e70110 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"55210_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106214","volume":"175","author":"X Luo","year":"2022","unstructured":"Luo, X. et al. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy. Eur. J. Pharm. Sci. 175, 106214 (2022).","journal-title":"Eur. J. Pharm. Sci."},{"key":"55210_CR28","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.12998\/wjcc.v10.i31.11466","volume":"10","author":"J-L Wang","year":"2022","unstructured":"Wang, J.-L. et al. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis. World J. Clin. Cases 10, 11466\u201311485 (2022).","journal-title":"World J. Clin. Cases"},{"key":"55210_CR29","doi-asserted-by":"crossref","unstructured":"\u00d6zkaraka\u015f, H. et al. Risks of polymyxin B nephrotoxicity and its precursors in the intensive care unit: A retrospective cohort study. Cureus 15 (2023).","DOI":"10.7759\/cureus.44301"},{"key":"55210_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1533177","author":"Y Yu","year":"2025","unstructured":"Yu, Y., He, Z. & Wang, C. Monte Carlo simulation to optimize polymyxin B dosing regimens for the treatment of Gram-negative bacteremia. Front. Cell. Infect. Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2025.1533177 (2025).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"55210_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107844","volume":"154","author":"S Zhou","year":"2025","unstructured":"Zhou, S. et al. Predictive factors for 30-day mortality after polymyxin B treatment of carbapenem-resistant Gram-negative bacilli infections. Int. J. Infect. Dis. 154, 107844 (2025).","journal-title":"Int. J. Infect. Dis."},{"key":"55210_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050470","volume":"10","author":"DT Sathyapalan","year":"2021","unstructured":"Sathyapalan, D. T. et al. Antimicrobial stewardship and its impact on the changing epidemiology of polymyxin use in a South Indian healthcare setting. Antibiotics 10, 470 (2021).","journal-title":"Antibiotics"},{"key":"55210_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100676","volume":"9","author":"C Adembri","year":"2020","unstructured":"Adembri, C., Novelli, A. & Nobili, S. Some suggestions from PK\/PD principles to contain resistance in the clinical setting-focus on ICU patients and Gram-negative strains. Antibiotics 9, 676 (2020).","journal-title":"Antibiotics"},{"key":"55210_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101557","volume":"12","author":"H Giamarellou","year":"2023","unstructured":"Giamarellou, H., Galani, L., Karavasilis, T., Ioannidis, K. & Karaiskos, I. Antimicrobial stewardship in the hospital setting: A narrative review. Antibiotics 12, 1557 (2023).","journal-title":"Antibiotics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55210-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:02:34Z","timestamp":1786708954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55210-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55210"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55210-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to participation in the study. Consent included permission to audio-record interviews and to use anonymized quotations for publication purpose.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25420"}}